Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6521
    +0.0002 (+0.04%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    108,551.38
    +1,612.05 (+1.51%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6042
    +0.0008 (+0.13%)
     
  • AUD/NZD

    1.0905
    +0.0003 (+0.03%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,358.44
    +190.37 (+0.47%)
     

The Zacks Analyst Blog Highlights: Toyota, Netflix, AbbVie, Gilead and Fiserv

For Immediate Release

Chicago, IL –November 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Toyota Motor TM, Netflix NFLX, AbbVie ABBV, Gilead Sciences GILD and Fiserv FISV.

Here are highlights from Monday’s Analyst Blog:

Top Research Reports for Toyota, Netflix and AbbVie

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Toyota Motor, Netflix and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Toyota’s shares have outperformed the Zacks Foreign Automotive industry year to date (24.4% vs. 15.2%). The Zacks analyst believes that Expanding portfolio of product lines is driving the firm’s sales.

In order to capitalize on the accelerated global shift to electric cars, the auto giant of Japan is deepening focus on developing electric and autonomous vehicles, which will bolster the company’s product competitiveness. Its healthy balance sheet, improving cash flows and investor-friendly moves are other positives.

However, anticipating a slowdown in India, Indonesia and Thailand, the company narrowed its annual vehicle sales target for fiscal 2020. High research and development expenses on advanced technologies for the development of EVs and driverless cars are likely to dent near-term margins. As such, investors are recommended to wait for a better entry point.

(You can read the full research report on Toyota here >>>)

Shares of Netflix have lost 15.6% in the past six months against Zacks Broadcast Radio and Television industry’s fall of 5.1%. The Zacks analyst believes that Netflix’s third-quarter 2019 subscriber addition rate faltered primarily due to a price hike in the United States, which, however aided ARPU growth on a year-over-year basis.

Management now expects net additions in the paid subscriber base to decline in 2019 due to higher churn rate and increased competition. Notably, upcoming streaming services from Disney, Apple, Comcast and AT&T pose a significant threat to Netflix’s streaming dominance. Shares have underperformed the industry on a year-to-date basis.

Moreover, high streaming content obligation and increased spending are expected to hurt free cash flow generation. Nevertheless, a solid content portfolio and expanding bundle-offerings through partnerships with Telefonica, KDDI, AT&T, Comcast, DISH, Verizon, Charter, Altice, T-Mobile and Sky bode well for the streaming platform.

(You can read the full research report on Netflix here >>>)

AbbVie’s shares have gained 32% over the past three months against the Zacks Large Cap Pharmaceuticals industry’s rise of 5.6%. The Zacks analyst believes that AbbVie’s key drug, Humira is performing well based on strong demand trends despite new competition. Imbruvica has multibillion-dollar potential.

AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, it has an impressive late-stage pipeline. It gained approvals for two new drugs with significant potential, Skyrizi (risankizumab) and Rinvoq, this year. Both are off to a strong start.

The acquisition of Allergan, if successful, should diversify AbbVie’s revenue base and accelerate its non-Humira business. However, AbbVie’s shares have underperformed the industry this year so far. Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind.

(You can read the full research report on AbbVie here >>>)

Other noteworthy reports we are featuring today include Gilead Sciences and Fiserv.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com  

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Netflix, Inc. (NFLX) : Free Stock Analysis Report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Toyota Motor Corporation (TM) : Free Stock Analysis Report
 
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
 
Fiserv, Inc. (FISV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research